Sotatercept

Therapeutic indications

Sotatercept is indicated for:

Pulmonary arterial hypertension

Population group: only adults (18 years old or older)

Sotatercept, in combination with other pulmonary arterial hypertension (PAH) therap ies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.3 mg/kg as a single starting dose for 3 weeks and thereafter 0.7 mg/kg once every 3 weeks

Contraindications

Sotatercept is contraindicated in the following cases:

Lactation

Patients with platelet counts consistently <50 x 10⁹/L before initiating treatment

Platelet count below reference range

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.